Information for Patients with Gastric Cancer and Their Relatives and Friends Regarding Gastric Cancer, Treatment and Today’s Changing Health Care.
Gastric cancer, or stomach cancer, affects many people worldwide, and diagnosis of the disease makes patients and their relatives and friends concerned and anxious as to what sort of treatment might be required and how best to participate in decisions regarding their health care.
Understanding several points with respect to the cancer itself, the various options available for its treatment, and the part played by individual measurements to choose an appropriate treatment all contribute to a patient’s ability to take an active role regarding their treatment. HER2 positive gastric cancer is defined by elevated levels of HER2 protein expression or HER2 gene amplification in the tumor cells.
Importantly, HER2 status alone does not determine treatment for patients with stomach cancer. Other important factors such as cancer, other biomarkers, prior treatments, and overall patient health, as well as individual treatment goals, must also be taken into consideration by physicians when determining the best course of her2 positive stomach cancer treatment for their patients.
Why HER2 Testing Matters
Most HER2 testing is done on a sample of tumor tissue from a patient’s biopsy or from the tissue removed during surgery. The amount of HER2 proteins on the surface of cancer cells can be measured by using immunohistochemistry (IHC) tests. In addition, HER2 genes in cancer cells can be measured by using in situ hybridization (ISH) tests to see if they have been amplified.
Because IHC measures only the amount of HER2 protein in cancer cells and not how much mRNA for HER2 is made, some IHC positive cases may require additional testing to determine a final classification of HER2 positive. These tests include ISH with FISH for detection of HER2 gene amplification.
Some other tumor biomarkers include PD-L1 (programmed death-ligand 1) and the mismatch repair proteins (MMR) for testing microsatellite instability (MSI).
Patients must remind their oncologists to explain to them the results of the pathology report, the meaning of the test results reported on the document and whether other tests are needed to determine the better treatment for their case.
How Cancer Stage Shapes Treatment Decisions
Gastric cancer can be localized, meaning it has not spread to distant parts of the body. For such cases, the aim of treatment is often to try to cure the disease. The approach to treatment depends on the location of the primary tumor and on the cancer stage. Treatment may include surgery followed by chemotherapy or surgery with the start of chemotherapy before surgery.
For patients with advanced and/or metastatic stomach cancer, the goal of treatment is to stop the growth of the cancer and to control symptoms of the cancer in order to extend life and to improve the patient’s quality of life.
These treatments are given as systemic therapy using chemo, target, and/or immunotherapy depending on the circumstances of the individual patient. Two people with HER2 positive gastric cancer can have different treatment options for several reasons. One reason is the stage of cancer. For example, locally advanced cancer can be treated differently than metastatic cancer even if both tumors are HER2 positive.
Targeted Therapy and Evolving Treatment Options
For some patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer, immunotherapy may be a treatment option depending on factors such as biomarker status, prior treatment history, and approved indications. Tislelizumab is a PD-1 inhibitor designed to help the immune system recognize and respond to cancer cells by blocking the PD-1 pathway, which can evade immune detection.
Tislelizumab may be used in combination with chemotherapy for certain patients with advanced gastric or gastroesophageal junction cancer, based on tumor characteristics, treatment guidelines, and approved indications. Chemotherapy regimens may include fluoropyrimidine- and platinum-based agents, with treatment selection influenced by factors such as a patient's overall health, organ function, prior therapies, and ability to tolerate treatment-related side effects.
Treatment decisions are individualized and should be made in consultation with an oncology team, considering the patient's specific diagnosis, disease characteristics, and treatment goals. Treatment options and their availability may vary between countries. Patients researching advanced gastric or gastroesophageal junction cancer treatment should discuss with their healthcare team which therapies are available and appropriate for their individual circumstances.
Disclaimer: The information provided in this article is intended for educational purposes only and should not be interpreted as medical advice, a clinical guideline, or a recommendation for any specific treatment.
